XBIO - ゼネティック・バイオサイエンシズ （Xenetic Biosciences Inc.） ゼネティック・バイオサイエンシズ

HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ: XBIO ) from Buy to Neutral , citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic announced a one-for-ten reverse stock split , the second … Full story available on Benzinga.com

Gainers NeoGames S.A. (NASDAQ: NGMS ) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 1847 Holdings LLC (NASDAQ: EFSH ) gained 64.5% to $0.9050 after the company reported a 27.6% increase in revenue to $15.4 million and achieved profitability for the first quarter. Harbor Custom Development, Inc. (NASDAQ: HCDI ) surged 49.5% to $8.97 following first-quarter results. WiSA Technologies, Inc. (NASDAQ: WISA ) rose 47.4% to $2.33 after the company signed a Letter of Intent to acquire Comhear. WiSA expects acquisition to be accretive beginning in the fourth quarter and sees FY24 revenue of $10 million to $15 million. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) gained 39% to $3.94 as the company said that its Chinese partner, HTIT, has successfully completed a Phase 3 oral insulin clinical trial and submitted a marketing authorization application in China. LM Funding America, Inc. (NASDAQ: LMFA ) jumped 34% to $0.9816 following better-than-expected results for the first quarter.

Xenetic Biosciences (XBIO) has announced it will effect a one-for-ten reverse stock split of its outstanding common stock, effective May 15, 2023.The company expects that upon the…

https://www.investing.com/news/assorted/xenetic-biosciences-announces-1for10-reverse-stock-split-of-common-stock-432SI-3081529

FRAMINGHAM, MA / ACCESSWIRE / May 12, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today …

Xenetic Biosciences press release (XBIO): FY Net loss of $6.6MThe Company ended the year with approximately $13.1 million of cash.

- Year marked by transformational strategic license of the DNase oncology platform and shift in focus to treatment of locally advanced or metastatic solid tumors - DNase program progressing towards Phase 1 clinical development - Closed the year with $13.1 million of cash expected to fund operations and drive pipeline development FRAMINGHAM, MA / ACCESSWIRE / March 23, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the full year 2022 and provided a business update. "2022 represented a transformational year for the Company. We expanded our oncology pipeline and bolstered our potential for key inflection points. We have continued to execute on our development plans for the DNase platform and are encouraged by our progress towards creating a near-term clinical development opportunity. We believe that our DNase platform, comprising multiple treatment modalities, has the potential to generate much needed therapies for pancreatic carcinoma and other locally advanced or metastatic solid tumors, and we are excited to unlock the full potential of our assets," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET -FREN…

- Live moderated video webcast with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29 th at 11:00 AM ET - FRENCHTOWN, NJ / ACCESSWIRE / March 16, 2023 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor NETs in Cancer Spotlight Event featuring Xenetic Biosciences on Wednesday, March 29, 2023, at 11:00 AM ET. Access the event here . Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers. The Company''s DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

Xenetic Biosciences (XBIO) stock rose ~14% on Tuesday after the company said that the Canadian Intellectual Property Office ((CIPO)) issued a notice of allowance for a patent covering…

Xenetic Biosciences (XBIO) stock rose ~14% on Tuesday after the company said that the Canadian Intellectual Property Office ((CIPO)) issued a notice of allowance for a patent covering…

Appointment of Dr. Spicer to Scientific Advisory Board bolsters expertise in Neutrophil Extracellular Traps ("NETs") in cancer biology and provides valuable assistance in advancing development of the Company''s DNase platformFRAMINGHAM, MA / …

Xenetic Biosciences press release (XBIO): Q3 GAAP EPS of -$0.06.Revenue of $411.95M.

– Continued advancement of lead technology, DNase-based oncology platform, in locally advanced or metastatic solid tumors towards Phase 1 clinical development– Ended the quarter with $13.8 million of cash expected to fund operations and drive expanded pipeline development forward FRAMINGHAM, MA / ACCESSWIRE / November 10, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (“Xenetic” or the […]

Signing of patent assignment from CLS Therapeutics as part of a collaboration agreement with Volition and CLS Therapeutics to develop NETs-targeted adoptive cell therapies for the treatment of cancer FRAMINGHAM, MA / ACCESSWIRE / October 11, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced the signing of a patent assignment from CLS Therapeutics, Inc. ("CLS") to Xenetic related to Xenetic''s previously announced collaboration with VolitionRx Limited (NYSE AMERICAN:VNRX) ("Volition"), a multi-national epigenetics company, and CLS, a biopharmaceutical company developing first-in-class therapies based on the discovery of novel therapeutic targets. In consideration of the patent assignment, Xenetic will also issue 850,000 shares of common stock to CLS. "Our team remains intent on driving the DNase technology platform forward with the goal of improving outcomes of existing therapeutic agents in multiple solid tumor indications for which existing therapeutic agents have not been proven to be effective.